| Grant number: | 15/03254-9 |
| Support type: | Scholarships abroad - Research Internship - Doctorate |
| Effective date (Start): | September 01, 2015 |
| Effective date (End): | November 30, 2015 |
| Field of knowledge: | Interdisciplinary Subjects |
| Principal researcher: | Maria Alice da Cruz Hofling |
| Grantee: | Monique Culturato Padilha Mendonça |
| Supervisor abroad: | István Krizbai |
| Home Institution: | Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil |
| Research place: | Hungarian Academy of Sciences (HAS), Hungary |
| Associated to the scholarship: | 12/24782-5 - Graphene oxide and central nervous system: evaluation of effects on blood brain barrier and nanotoxicological profile, BP.DR |
Abstract The blood-brain barrier (BBB) is a complex physical and functional barrier that protects the central nervous system (CNS) from physical and chemical insults. Nevertheless, it also constitutes a barrier against therapeutics for treating CNS diseases. In this context, nanomedicine is a promising field of study to help to overcome this problem. In a previous study, we have demonstrated the diffusion and spatial distribution of graphene oxide nanoparticles (GO-NPs) over time in the rat CNS after intravenous injection. However, the mechanisms of GO-NPs uptake remains still an open question. In order to advance in the understanding on the interactions GO-NP-tissue cells, we are applying for a three months leave to be spent in a laboratory with expertise in in vitro models of blood-brain barrier. Particularly, the relevance of in vitro models of blood-brain barrier for the evaluation of drug nanocarrier uptake and nanotoxicoloy assessment is notorious. In addition, BBB in vitro models possess improved transport properties that can be easily monitored over time with lower laboratory costs and no need of experimental animals. We hope our understanding of these basic mechanisms will help to designing new types of nanocarriers as brain delivery systems that will advance drug therapy in diseases affecting the CNS. (AU) | |